English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background Evidence for ceftolozane/tazobactam use in children is limited. We describe herein the outcomes of children treated with TOL/TAZ for various types of infections caused by carbapenem-resistant Pseudomonas aeruginosa (CR-PA). Methods Retrospective analysis of children who received TOL/TAZ while hospitalized from 2014 to 2017. Clinical and microbiological outcomes and safety data were analyzed. Results 8 children received TOL/TAZ for CR-PA infections (table): 3 cystic fibrosis (CF) exacerbations, 2 ventilator-associated pneumonia (VAP), 1 tracheitis, 1 chronic osteomyelitis (OM), 1 complicated intra-abdominal infection with urinary tract infection (cIAI/cUTI). All initial isolates were susceptible to TOL/TAZ per E-test. Creatinine clearance (CrCl) >90 mL/minute in all patients. Median total length of stay (LOS) was 73 days (d) (range 11–221) and median inpatient duration of TOL/TAZ was 13.5 d (range 5–61). One patient died from causes unrelated to infection; all other patients achieved clinical cure and TOL/TAZ was well tolerated. One patient experienced a slight increase in liver function tests that required dose reduction. 3 children received multiple courses (range: 2–8) for CF exacerbations. TOL/TAZ-resistant PA was detected in 1 patient after 2 months of therapy for OM. TOL/TAZ intermediately susceptible PA was detected in 1 patient after 7 courses of therapy for CF exacerbation, though subsequent cultures grew TOL/TAZ susceptible PA. Conclusion TOL/TAZ was effective in treating various CR-PA infections. Therapy was well tolerated with no significant adverse events. Reduced TOL/TAZ susceptibility after prolonged or repeated courses was observed and presents potential opportunities for dose optimization and antimicrobial stewardship. Pt # Age, years Indication CrCl, mL/minute Dose, TOL mg/kg (g) per dose every 8 hours Duration, days LOS, days # of courses 30 days readmit (Y/N) 1 14 cIAI/cUTI 139 13.8 (1.5) 19 142 1 N 2 16 OM 155 16.2 (1.5) 61 221 1 N 3 19 CF 95 34.8 (3) 9 14 2 Y 4 17 VAP 223 32.3 (3) 17 65 1 N 5 14 CF 142 30 (1.5) 15 36 7 N 6 11 CF 148 21.3 (1.5) 5 11 3 Y 7 0.25 VAP 198 20 (0.08) 12 98 1 N 8 3 Tracheitis 145 18.8 (0.25) 10 81 1 N Disclosures All authors: No reported disclosures.

2423. Effectiveness and Safety of Ceftolozane/Tazobactam (TOL/TAZ) Use for Carbapenem-Resistant Pseudomonas Infections in Children